Crypto market cap $2.14 T −4.25%24h volume $85.6 BBTC dominance 58.0%Fear & Greed 12/100BTC $62,043.90 −2.56%ETH $1,756.69 −2.65%S&P 500 (SPY) $715.87 −1.96%Gold $3,580.40 −2.85%Updated 2026-11-20
★ 💼

What's happening with Insmed (INSM)? Shares jump 21% on a report that Sanofi is weighing a takeover

Insmed closed up about 20.6% at $144.46 on November 19 after Bloomberg reported that Sanofi is exploring a bid for the roughly $26.6 billion lung-disease drugmaker. Neither company has confirmed talks.

Insmed, the US biotech behind the lung-disease drug Brinsupri, had its best day in a long time on Thursday — not because of a trial result, but because of a takeover rumour. A report that French drugmaker Sanofi is studying a deal sent the stock up more than a fifth.

What happened

  • Thursday, November 19, US session. Bloomberg, citing people familiar with the matter, reported that Sanofi is working with advisers on a possible acquisition of Insmed.
  • The stock spiked. INSM jumped more than 18% within minutes and was briefly halted by a volatility circuit breaker. It closed at about $144.46, up roughly 20.6% from $119.80 the day before.
  • Size of a possible deal. Before the jump Insmed was valued at about $26.6 billion — close to a quarter of Sanofi's own market value of roughly €101 billion. A deal of that size would be one of the largest biotech takeovers in years.
  • Nothing confirmed. Both companies declined to comment. No price or premium has been reported, talks could still take weeks, and there is no guarantee of an agreement; other bidders could also appear.

Why it moved

This is a classic takeover-report jump: traders bid the shares up toward a price a buyer might pay. Insmed was an easy target for the story. Its shares had fallen about 40% over the previous 12 months, while Brinsupri — the first approved treatment for non-cystic fibrosis bronchiectasis, a chronic lung condition — gives a big pharma company a ready-made growth product. Big drugmakers are hunting for exactly that as patents on their older blockbusters run out.

The flip side: if the talks fall apart, a rumour-driven gain can disappear as quickly as it came.

The numbers right now

Insmed trades at $144.46. Even after Thursday's move it is roughly 30% below its highest month-end level of about $208. See how other stocks compare with their peaks on our from-ATH page.

What it means if you buy regularly

A single headline added about a fifth to the share price in one afternoon — a reminder that biotech stocks move in jumps, not in straight lines. Someone who put $10 a day into Insmed over the last 5 years has invested $18,260 and now holds $71,929 (+294%). The same plan in the S&P 500 is worth $26,246 (+43.7%). That is history, not a forecast. Compare them in the DCA calculator.

Sources

Not investment advice.

👀 Track it on WhatIfStack

Add these assets to your free watchlist or portfolio — live prices, profit and news in one place, no sign-up.

📬 Weekly markets report

Once a week: what happened to crypto, stocks and gold, the best and worst assets, and our top articles. No spam.

Only the weekly report. Unsubscribe in one click from any e-mail.

WhatIfStack news

Follow us
TelegramX (Twitter)BlueskyMediumPinterest✉ support@whatifstack.com🤝 partners@whatifstack.com
Popular
BitcoinEthereumSolanaXRPNvidiaAppleTeslaGoldS&P 500 ETFNasdaq-100 ETF
Markets
MarketsCompareCryptocurrencyStockETFMetalCommodityUnited KingdomCanadaAustraliaUnited StatesUkraine
Tools
CompareConverterLargest companiesFamous investorsLargest assetsMemecoinsBitcoin halvingCalculators
Insights
GuideNewsInsightsRSSActivitiesExchangesAbout & methodologyEditorial policyFor partners & advertisers